Other formats:
BibTeX
LaTeX
RIS
@article{2213959,
author = {Hussain, Mohammad Salman and Singh, A. and Antony, B. and Klugarová, Jitka and Murad, M. H. and Jayraj, A. S. and Langaufová, Alena and Klugar, Miloslav},
article_location = {Basel},
article_number = {16},
doi = {http://dx.doi.org/10.3390/jcm11164675},
keywords = {hypertension; preeclampsia; proton pump inhibitors; PPIs; pregnancy; meta-analysis},
language = {eng},
issn = {2077-0383},
journal = {Journal of Clinical Medicine},
title = {Proton Pump Inhibitors Use and Risk of Preeclampsia: A Meta-Analysis},
url = {https://www.mdpi.com/2077-0383/11/16/4675},
volume = {11},
year = {2022}
}
TY - JOUR
ID - 2213959
AU - Hussain, Mohammad Salman - Singh, A. - Antony, B. - Klugarová, Jitka - Murad, M. H. - Jayraj, A. S. - Langaufová, Alena - Klugar, Miloslav
PY - 2022
TI - Proton Pump Inhibitors Use and Risk of Preeclampsia: A Meta-Analysis
JF - Journal of Clinical Medicine
VL - 11
IS - 16
SP - 1-15
EP - 1-15
PB - MDPI
SN - 20770383
KW - hypertension
KW - preeclampsia
KW - proton pump inhibitors
KW - PPIs
KW - pregnancy
KW - meta-analysis
UR - https://www.mdpi.com/2077-0383/11/16/4675
N2 - Evidence from preclinical studies suggests a preventive effect of proton pump inhibitors (PPIs) in preeclampsia. Recently, several epidemiological studies have described a conflicting association between the use of PPIs during pregnancy and preeclampsia risk. This study aimed to evaluate the association between PPI use and the risk of preeclampsia. We searched databases, including MEDLINE, Embase, Scopus, Web of Science Core Collection, Emcare, CINAHL, and the relevant grey literature from inception until 13 September 2021. Studies reporting the preeclampsia risk with the use of PPIs were eligible for inclusion. Literature screening, data extraction, and the risk of bias assessment were performed independently by two investigators. Random-effect meta-analysis was performed to generate relative risks (RR) and 95% confidence intervals (CI). The risk of preeclampsia and preterm preeclampsia among women receiving PPIs during pregnancy were the primary outcomes of interest. This meta-analysis comprised three studies involving 4,877,565 pregnant women, of whom 119,017 were PPI users. The included studies were judged to have a low risk of bias. The risk of preeclampsia among pregnant women who received PPIs anytime during pregnancy was significantly increased (RR 1.27 (95% CI: 1.23–1.31)), although the increase was trivial in absolute terms (2 per 1000). The subgroup analysis revealed that the risk was increased in each of the three trimesters. The risk of preterm preeclampsia among pregnant women receiving PPIs anytime during pregnancy was not significantly increased (RR 1.04 (95% CI: 0.70–1.55)). The certainty evaluated by GRADE in these estimates was low. PPI use may be associated with a trivial increase in the risk of preeclampsia in pregnant women. There is no evidence supporting that PPI use decreases the risk of preeclampsia or preterm preeclampsia.
ER -
HUSSAIN, Mohammad Salman, A. SINGH, B. ANTONY, Jitka KLUGAROVÁ, M. H. MURAD, A. S. JAYRAJ, Alena LANGAUFOVÁ and Miloslav KLUGAR. Proton Pump Inhibitors Use and Risk of Preeclampsia: A Meta-Analysis. \textit{Journal of Clinical Medicine}. Basel: MDPI, 2022, vol.~11, No~16, p.~1-15. ISSN~2077-0383. Available from: https://dx.doi.org/10.3390/jcm11164675.
|
